Researchers outline their improved lipid-polymer nanoparticle for holding mRNA that is stable when nebulized and successfully ...

Researchers outline their improved lipid-polymer nanoparticle for holding mRNA that is stable when nebulized and successfully ...

A groundbreaking study introduces stable inhalable mRNA treatment using nanoparticles that hold up during nebulization, ...

Received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung ...

DUBLIN, Nov. 12, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third quarter of 2024 ...

In this article, we take a look at five biotech companies developing potentially transformative medicines to treat cystic ...

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more ...

UTHR reports better-than-expected results in third-quarter 2024 on the back of strong demand for its treprostinil medications, especially Tyvaso.

Argus analyst Jasper Hellweg raised the firm’s price target on United Therapeutics (UTHR) to $400 from $360 and keeps a Buy rating on the ...

Oct 30, 2024--United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced it ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...